Johns Hopkins Researchers Develop Novel Intranasal DNA Vaccine Targeting Drug-Tolerant TB Bacteria, Offering New Hope Against Global Health Scourge.

Researchers at Johns Hopkins Medicine and the Johns Hopkins Bloomberg School of Public Health have achieved a significant breakthrough in the fight against tuberculosis (TB), developing an experimental therapeutic DNA vaccine delivered through the nose. This innovative vaccine is specifically engineered to bolster the immune system’s capacity to identify and neutralize drug-tolerant TB bacteria, commonly referred to as "persisters." These resilient microbes are notorious for surviving prolonged antibiotic treatments, often leading to a debilitating relapse of the disease. The groundbreaking findings, which could herald a new era in TB treatment, were officially published in the esteemed Journal of Clinical Investigation.

Tuberculosis, an ancient adversary of humanity, has plagued populations for at least 6,000 years, leaving an indelible mark on human history and health. Despite millennia of struggle and significant advancements in medicine, it tragically remains one of the world’s deadliest infectious diseases. The statistics paint a stark picture of its pervasive global impact. According to the World Health Organization (WHO), a staggering one-quarter of the global population—approximately 2 billion people—harbor latent TB infections, meaning they carry the bacteria without exhibiting symptoms. While latent infections are not immediately dangerous, they represent a vast reservoir for future active disease. In 2024 alone, more than 10 million individuals developed active TB, and a tragic 1.2 million succumbed to the disease, solidifying its grim status as the leading cause of death from a single infectious pathogen, surpassing even HIV/AIDS in its lethality.

The Persistent Global Challenge of Tuberculosis

The sheer scale of TB’s burden underscores an urgent need for novel and more effective treatment and prevention strategies. The current standard of care for active TB involves lengthy and complex multidrug regimens, typically lasting six to nine months, and even longer—up to 18-24 months—for drug-resistant forms. While these regimens are effective when completed, their protracted nature often leads to poor patient adherence, a critical factor contributing to treatment failures, disease relapse, and the escalating emergence of drug-resistant strains.

The WHO has consistently emphasized the imperative for new approaches, particularly therapeutic vaccines that can complement existing drug treatments. Such vaccines hold immense promise, offering the potential to drastically shorten lengthy treatment regimens, improve patient outcomes, and mitigate the challenges associated with multidrug therapies, especially in regions grappling with the widespread transmission of drug-resistant TB. The findings from the new Johns Hopkins study represent a significant step towards addressing these multifaceted challenges.

Dr. Styliani Karanika, a leading figure in the study and a faculty member of the Johns Hopkins Center for Tuberculosis Research and assistant professor of medicine at the Johns Hopkins University School of Medicine, highlighted the vaccine’s efficacy in preclinical models. "Administered together with first-line TB drug therapy, our intranasal DNA fusion vaccine helped infected mice clear the disease bacteria faster, reduced lung inflammation and prevented relapse after treatment ended," Dr. Karanika stated. "The vaccine also helped the powerful TB drug combination of bedaquiline, pretomanid and linezolid work better, suggesting it could be used with treatments against drug-resistant TB to help the body fight the disease, even hard-to-treat cases." This indicates the vaccine’s potential not just as a standalone therapy, but as an adjunctive treatment that could enhance the effectiveness of even the most potent drug cocktails currently available for drug-resistant TB, a form of the disease that poses a severe threat to global health security.

Understanding the Mechanism: How the Experimental TB Vaccine Works

The ingenuity of the Johns Hopkins vaccine lies in its sophisticated biological design and delivery method. According to Dr. Karanika, the vaccine is a DNA fusion construct that combines two specific genes: relMtb and Mip3α. The choice of intranasal delivery is not arbitrary; it strategically leverages several biological mechanisms believed to significantly strengthen immunity against TB, particularly within the respiratory system where the infection primarily takes hold.

Delving into the specifics of its mechanism, Dr. Karanika elaborated on the role of the relMtb gene. "First, TB bacteria possess a gene, relMtb, that produces a protein, RelMtb, to help the microbes survive hostile conditions such as antibiotic exposure, low oxygen and nutrient limitation by entering a drug-tolerant persistent state," she explained. This "persistent state" is precisely what makes TB so difficult to eradicate, as these dormant bacteria are largely impervious to antibiotics that target actively replicating cells. The vaccine ingeniously exploits this vulnerability. "Fusing relMtb with the Mip3α gene produces a signal that attracts immature dendritic cells — key cells that pick up TB proteins and ‘present’ them to T cells, the immune cells that help coordinate a targeted attack on the TB bacteria." Dendritic cells act as critical sentinels of the immune system, bridging the innate and adaptive immune responses by capturing antigens and presenting them to T lymphocytes, thereby initiating a highly specific and potent immune reaction.

Furthermore, the design of the vaccine is deliberately focused on concentrating immune activity at the primary site of TB infection: the respiratory tract. "Finally, intranasal delivery focuses vaccination on the respiratory mucosa in the lungs where TB infection occurs, helping generate long-lasting localized T-cell immunity in the airways and lungs, along with systemic immune responses," Dr. Karanika added. This direct delivery to the mucosal surfaces of the respiratory system is crucial because it elicits a robust local immune response, including the generation of memory T-cells that can swiftly recognize and eliminate TB pathogens upon re-exposure, providing a fortified first line of defense. This strategy is distinct from traditional intramuscular vaccines, which primarily induce systemic immunity.

Robust Immune Responses Observed in Preclinical Studies

The strategic combination of these immunological mechanisms was intended to fortify immune defenses directly within the respiratory tract. The results from rigorous animal experiments provided compelling evidence of the vaccine’s efficacy. In mouse models, the intranasal DNA vaccine significantly enhanced the recruitment and activation of dendritic cells, crucial for initiating an adaptive immune response. Researchers also observed improved organization of dendritic cells and T cells within lung tissue, indicating a more coordinated and effective immune attack. Crucially, the vaccine generated durable, antigen-stimulated T-cell responses—both locally within the lungs and systemically throughout the body—encompassing both CD4 (helper T cells) and CD8 (killer T-cells). Helper T cells play a central role in orchestrating immune responses, while killer T-cells are essential for directly eliminating infected cells.

To further validate these promising findings and bridge the gap towards human application, the research team also evaluated the vaccine in rhesus macaques, a nonhuman primate model whose immune system more closely resembles that of humans. The nose-delivered DNA vaccine successfully generated measurable TB-specific immune responses in both the bloodstream and the airways of these primates. These observed responses were strikingly similar to those associated with reduced bacterial levels in the lungs of vaccinated mice, providing an encouraging indication of its potential translation to humans.

The researchers were particularly heartened to observe that these immune responses in macaques lasted for at least six months, suggesting that the vaccine may confer durable protection against the pathogen. However, Dr. Karanika prudently noted a critical limitation of the primate study: it primarily assessed immune activation and did not involve directly challenging the animals with an actual TB infection to test protective efficacy. This is a standard step in preclinical development, and further research will be required before the vaccine can advance to human clinical trials, which represent the next critical phase in its development.

"These nonhuman primate data are encouraging because they show that the Mip3α/relMtb vaccine can generate durable, antigen-stimulated immune responses in an animal model whose immune system more closely resembles that of humans," Dr. Karanika affirmed. "That gives us an important translational bridge between the mouse efficacy studies and the additional preclinical work needed before human trials." This "translational bridge" is vital for de-risking human trials and ensuring that the biological mechanisms observed in simpler models are likely to hold true in more complex systems.

Targeting TB Persisters: A Paradigm Shift in Treatment Strategy

The researchers firmly believe that their results support a broader and potentially transformative treatment strategy. This strategy centers on the elimination of TB "persisters" through immunotherapy, moving beyond an exclusive reliance on antibiotics to kill actively growing bacteria. This represents a significant shift in thinking, acknowledging that a multifaceted approach incorporating immune-modulating therapies may be necessary to fully conquer TB. The unique ability of DNA vaccines to deliver genetic material directly to cells, stimulating an immune response, offers distinct advantages. DNA vaccines are generally stable, can be produced efficiently, and are relatively easy to modify, offering practical benefits if future studies confirm similar therapeutic benefits in humans.

The development of this vaccine comes at a critical juncture in the global fight against TB. The emergence and spread of multidrug-resistant (MDR-TB) and extensively drug-resistant (XDR-TB) strains have severely complicated treatment efforts. MDR-TB, resistant to at least the two most powerful first-line anti-TB drugs (isoniazid and rifampicin), requires longer, more expensive, and often more toxic treatment regimens, with lower success rates. XDR-TB, resistant to even more potent second-line drugs, presents an even greater challenge, with limited treatment options and extremely poor outcomes. A therapeutic vaccine that targets persisters could be particularly impactful in these scenarios, helping the host immune system clear remaining bacteria even when traditional antibiotics struggle.

The Road Ahead: From Bench to Bedside

The journey from an experimental vaccine in animal models to a widely available human therapeutic is arduous, requiring extensive preclinical development, rigorous clinical trials, and regulatory approvals. The next steps will involve further optimization of the vaccine, more detailed toxicology studies, and ultimately, Phase 1 human trials to assess safety and immunogenicity in healthy volunteers. If successful, subsequent Phase 2 and Phase 3 trials would then evaluate efficacy in larger populations, including those with active TB.

The potential implications of a successful therapeutic TB vaccine are far-reaching. Such a vaccine could significantly shorten the duration of TB treatment, thereby improving patient adherence and reducing the rates of relapse and the development of drug resistance. For patients in low- and middle-income countries, where the burden of TB is highest and access to lengthy, complex drug regimens can be challenging, a shorter, more effective treatment paradigm could be life-changing. It could also alleviate the immense strain on healthcare systems in these regions. Furthermore, by targeting persisters, the vaccine offers a novel mechanism to tackle the root cause of relapse, a persistent problem in TB management.

The research was a collaborative effort involving numerous individuals and institutions. Along with Dr. Karanika, the Johns Hopkins research team included Tianyin Wang, Addis Yilma, Jennie Ruelas Castillo, James Gordy, Hannah Bailey, Darla Quijada, Kaitlyn Fessler, Rokeya Tasneen, Elisa M. Rouse Salcido, Farah Shamma, Harley Harris, Fengyixin Chen, Rowan Bates, Heemee Ton, Jacob Meza, Yangchen Li, Alannah Taylor, Jean Zheng, Jiaqi Zhang, Theodoros Karantanos, Amanda Maxwell, Eric Nuermberger, J. David Peske, Richard Markham and Petros Karakousis. This extensive list underscores the interdisciplinary nature of modern scientific breakthroughs.

The study received substantial financial backing from federal sources, including National Institutes of Health grants R01AI148710, K24AI143447, P30AI18436, K08AI174959 and P30CA006973. Additional support came from a Gilead HIV Research Scholar Award, a Johns Hopkins University Tuberculosis Research Advancement Center Developmental Award, a Center for HIV/AIDS Developmental Award from the Johns Hopkins University Center for AIDS Research, a Willowcraft Foundation Award, a Johns Hopkins University Clinician Scientist Award and the Potts Memorial Foundation. Such diverse funding highlights the broad recognition of the critical importance of this research. Notably, Karanika, Gordy, Markham and Karakousis are inventors on patent PCT/US2023/065584 for the Mip3α/relMtb vaccine, signaling its potential for future commercialization and widespread deployment. The authors reported no conflicts of interest, ensuring the integrity and objectivity of the reported findings. This pioneering work offers a beacon of hope in the enduring global battle against tuberculosis, promising a future where this ancient disease may finally be brought under effective control.